Daily startup and blockchain data-wiki with interviews, Q&A's & discussions about funding rounds & investors.

RaisedToday moderators manually update and approve wiki edits - check back every 1-2h for approved submissions.

Contributed by laura998

Immunai

2 Disclosed Funding Rounds $80,000,000

0 Participating Investments


Therapeutics, Biotechnology, Machine Learning, Artificial Intelligence

Immunai is a biotech company that combines single cell genomics with ML algorithms to enable high resolution profiling of the immune system.

New York, New York, United States, North America (US)

Organizations in New York in Therapeutics,
Organizations in New York in Biotechnology,
Organizations in New York in Machine Learning,
Organizations in New York in Artificial Intelligence,
Organizations in New York in Therapeutics,
Organizations in New York in Biotechnology,
Organizations in New York in Machine Learning,
Organizations in New York in Artificial Intelligence,
Organizations in United States in Therapeutics,
Organizations in United States in Biotechnology,
Organizations in United States in Machine Learning,
Organizations in United States in Artificial Intelligence,
Organizations in North America in Therapeutics,
Organizations in North America in Biotechnology,
Organizations in North America in Machine Learning,
Organizations in North America in Artificial Intelligence

Investors in New York in Therapeutics,
Investors in New York in Biotechnology,
Investors in New York in Machine Learning,
Investors in New York in Artificial Intelligence,
Investors in New York in Therapeutics,
Investors in New York in Biotechnology,
Investors in New York in Machine Learning,
Investors in New York in Artificial Intelligence,
Investors in United States in Therapeutics,
Investors in United States in Biotechnology,
Investors in United States in Machine Learning,
Investors in United States in Artificial Intelligence,
Investors in North America in Therapeutics,
Investors in North America in Biotechnology,
Investors in North America in Machine Learning,
Investors in North America in Artificial Intelligence

East Coast (0 Investors) (0 Startups), Northeastern US (0 Investors) (0 Startups), Greater New York Area (0 Investors) (0 Startups)

Founded date (FR) 12, 2018

Founders (FR) Luis F Voloch, Daniel Wells, Noam Solomon, Ansuman Satpathy, Dan Littman

Operating Status (FR) Active (FR)

Funding Stage (FR) Early Stage Venture (FR)

Last Funding Type (FR) Series A (FR)

Company Type (FR) For Profit (FR)

Website (FR) www.immunai.com/

Contact (FR) Hunter Lookup


Twitter Link

LinkedIN Link

Wikipedia Link

Immunai is a biotech company that combines single-cell genomics with ML algorithms to enable high-resolution profiling of the immune system. Immunai's mission is to map the entire immune system and its functions using single-cell genomics and machine learning. Immunai leverages single-cell technologies to profile cells from a blood sample, and uses machine-learning algorithms (powered by its proprietary database) to map the hundreds of cell types and their states to create an immune profile. They work on biomarker discovery and insights that identify how a cell responds to its changing environment. The company is located in New York City, San Francisco, and Tel Aviv, Israel.

Date (FR) Round (FR) Raised (FR) Lead (FR)
February, 11, 2021 Series A (FR) $60,000,000 Schusterman Foundation, Duquesne Family Office, Dexcel Pharma, Catalio Capital Management
May, 14, 2020 Seed (FR) $20,000,000 Viola Group, TLV Partners

Immunai Investors (FR) (8)

Investor (FR) Lead? (FR) Round (FR) Participating Raise (FR) Date (FR) Partners (FR)
Schusterman Foundation Yes (FR) Series A (FR) $60,000,000 February, 11, 2021 -------
Duquesne Family Office Yes (FR) Series A (FR) $60,000,000 February, 11, 2021 -------
Viola Group No (FR) Series A (FR) $60,000,000 February, 11, 2021 -------
Dexcel Pharma Yes (FR) Series A (FR) $60,000,000 February, 11, 2021 -------
TLV Partners No (FR) Series A (FR) $60,000,000 February, 11, 2021 -------
Catalio Capital Management Yes (FR) Series A (FR) $60,000,000 February, 11, 2021 -------
Viola Group Yes (FR) Seed (FR) $20,000,000 May, 14, 2020 -------
TLV Partners Yes (FR) Seed (FR) $20,000,000 May, 14, 2020 -------